Avinger, Inc. (AVGR): Price and Financial Metrics


Avinger, Inc. (AVGR)

Today's Latest Price: $0.34 USD

0.01 (4.43%)

Updated Dec 4 4:00pm

Add AVGR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

AVGR Stock Summary

  • AVGR has a higher market value than just 9% of US stocks; more precisely, its current market capitalization is $26,325,844.
  • With a year-over-year growth in debt of 46.22%, Avinger Inc's debt growth rate surpasses 80.68% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AVGR comes in at -98.85% -- higher than that of only 3.69% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Avinger Inc, a group of peers worth examining would be URG, MBII, XERS, HTGM, and ICAD.
  • Visit AVGR's SEC page to see the company's official filings. To visit the company's web site, go to www.avinger.com.

AVGR Stock Price Chart Interactive Chart >

Price chart for AVGR

AVGR Price/Volume Stats

Current price $0.34 52-week high $1.51
Prev. close $0.32 52-week low $0.21
Day low $0.33 Volume 24,000,000
Day high $0.39 Avg. volume 5,277,167
50-day MA $0.29 Dividend yield N/A
200-day MA $0.39 Market Cap 28.63M

Avinger, Inc. (AVGR) Company Bio


Avinger, Inc. designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the United States and Europe. The company was founded in 2007 and is based in Redwood City, California.


AVGR Latest News Stream


Event/Time News Detail
Loading, please wait...

AVGR Latest Social Stream


Loading social stream, please wait...

View Full AVGR Social Stream

Latest AVGR News From Around the Web

Below are the latest news stories about Avinger Inc that investors may wish to consider to help them evaluate AVGR as an investment opportunity.

Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma

Neurocrine presents encouraging three-year data for Parkinson’s treatment Neurocrine Biosciences Inc. (NBIX) reported that its data from PD-1101 study has demonstrated sustained improvement in motor function in patients with Parkinson’s disease. This Phase Ib open-label, three-year efficacy and safety study used investigational gene therapy, NBIb-1817. The average ‘Off’ time was...

Avisol Capital Partners on Seeking Alpha | September 18, 2020

Avinger (AVGR) Upgraded to Buy: Here's Why

Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo Finance | September 15, 2020

Avinger +28% on FDA clearance for Ocelaris

Avinger (AVGR) soars 28% in premarket, after the FDA grants 510(k) clearance to its Ocelaris, a next generation image-guided chronic total occlusion crossing system. The device will be marketed under the brand name TIGEREYE.The company says the device sports an improved image capture rate that provides high-definition intravascular imaging on par with its Pantheris...

Seeking Alpha | September 11, 2020

ROCE Insights For Avinger

Avinger (NASDAQ: AVGR) reported Q2 sales of $1.50 million. Earnings fell to a loss of $3.59 million, resulting in a 34.44% decrease from last quarter. In …

Benzinga | September 11, 2020

Avinger News: AVGR Stock Down 8% Following FDA Approval

Avinger (AVGR) news for Friday concerning approval from the FDA for one of its medical devices has AVGR stock on the move.

InvestorPlace | September 11, 2020

Read More 'AVGR' Stories Here

AVGR Price Returns

1-mo 45.30%
3-mo -19.05%
6-mo -24.44%
1-year -76.22%
3-year -99.63%
5-year -99.99%
YTD -70.18%
2019 -62.00%
2018 -95.83%
2017 -95.14%
2016 -83.71%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8198 seconds.